Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Title: Turning translational academic research into medicines for patients with genetic diseases

Speaker: Anna Hakes PhD, BridgeBio

Abstract/speaker bio: BridgeBio is a pharmaceutical company that finds, develops and delivers breakthrough medicines for genetic diseases. Founded in 2015 by a team of industry veterans, the company has built a portfolio of over 30 development programs ranging from discovery to Phase 3 clinical trials with two approved products. The company’s therapeutic areas include genetic dermatology, oncology, cardiology, neurology and endocrinology. BridgeBio continues to search for innovations originating in academia that can be translated into breakthrough therapies for genetic diseases and cancers with clear genetic drivers. BridgeBio is excited to introduce its partnering model to researchers at the University of Oxford as part of this seminar series. Please join us for a brief presentation, which will provide additional information regarding the company’s areas of interest, showcase some of its success stories and answer questions about how the company collaborates with its academic partners.

For further information on BridgeBio visit:




The Industry Insight Seminars provide a great opportunity to:

  • Increase awareness of commercial translation
  • Form connections between academics and industry 
  • Network with potential collaborators

These seminars are suitable for all scientists with some knowledge or interest in each topic area, from PhD students to PIs along with biotech, SMEs and Pharma companies.